Pharmacopeia received $5 million upfront and could receive up to $184 million more.
Pharmacopeia signed an exclusive research and license agreement with Wyeth Pharmaceuticals. The alliance is based on Pharmacopeia’s JAK3 inhibitor program and will be focused on the research, development, and commercialization of JAK3 inhibitor-based therapeutic products.
Inhibition of JAK3 has been shown in both preclinical and clinical studies to modulate disease outcomes, according to the companies. Given its function in activated T cells, it offers potential for treatments for rheumatoid arthritis, psoriasis, and certain other immunological conditions.
The companies each have the exclusive right to develop and commercialize products resulting from the collaboration. Pharmacopeia retains the right to dermatological products and treatments for ocular diseases via topical administration. Wyeth has the right to develop therapeutic products for all other indications and routes of delivery.
Pharmacopeia will receive a $5-million upfront payment and may also receive, over the next three years, up to $9 million in research funding. Pharmacopeia may also receive up to $175 million upon Wyeth's achievement of certain milestones, as well as double-digit royalties on the net sales of any products commercialized by Wyeth under the collaboration. Each company is responsible for all development, regulatory, manufacturing, and commercialization activities for the products it develops and commercializes in its field.